Decreases of GLUT1 expression have been previously detected by our group when reinducing thyroid cancer iodine-uptake with multikinase inhibitors, sorafenib/cabozantinib, which also target the MAPK pathway [6]. Here, SLC2A1 is linked to thyroid gland carcinoma.